Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug design: nitrosoureas.

G Eisenbrand, N Müller, J Schreiber

    IARC Scientific Publications
    |January 1, 1986
    PubMed
    Summary

    Researchers developed novel nitrosoureas for cancer treatment. One compound, HECNU, showed significant effectiveness against brain tumors, prompting further research into targeted drug delivery systems.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Dosimetry of human exposure to furan and 2-methylfuran by monitoring urinary biomarkers.

    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2024
    Same author

    [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].

    Pneumologie (Stuttgart, Germany)·2020
    Same author

    Sulfasalazine-induced mononucleosis-like-illness and haemolysis.

    Scandinavian journal of rheumatology·2020
    Same author

    [Treatment of rheumatic diseases and pulmonary toxicity].

    Der Pneumologe·2020
    Same author

    [Drug-induced disorders of the lung parenchyma].

    Der Pneumologe·2020
    Same author

    Sub-cycle dynamics in relativistic nanoplasma acceleration.

    Scientific reports·2019

    Area of Science:

    • Oncology
    • Medicinal Chemistry
    • Pharmacology

    Background:

    • Ongoing efforts to create superior and safer antineoplastic nitrosoureas.
    • Previous synthesis and preclinical evaluation of short-chain, water-soluble, lipophilic compounds: 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (HECNU) and 1-(2-chloroethyl)-1-nitroso-3-(methylene carboxamido)urea.

    Purpose of the Study:

    • To summarize the development of novel nitrosoureas with improved efficacy and reduced toxicity.
    • To investigate the molecular mechanisms of action, including DNA alkylation and carbamoylation.
    • To evaluate the clinical efficacy of HECNU in brain tumors and explore new delivery strategies.

    Main Methods:

    • Synthesis and preclinical testing of novel nitrosourea compounds.
    • Analysis of molecular mechanisms involving DNA alkylation, cross-linking, and glutathione interactions.

    Related Experiment Videos

  • Clinical phase-II study of HECNU in patients with brain tumors.
  • Structure-activity relationship study of oestradiol-linked nitrosourea analogues.

    • Main Results:

    • HECNU demonstrated significant activity in brain tumors, consistent with preclinical findings.
    • Molecular mechanisms elucidated include DNA alkylation, cross-linking, and inhibition of glutathione reductase.
    • An oestradiol-17 ester derivative showed enhanced activity compared to other oestradiol-linked analogues.

    Conclusions:

    • HECNU is a promising antineoplastic agent, particularly for brain tumors.
    • Carrier molecules, such as oestradiol derivatives, represent a viable strategy for future nitrosourea development.
    • Further research into targeted delivery systems is warranted to optimize therapeutic outcomes.